Lobe Sciences Ltd. Upsizes Private Placement

Lobe Sciences Ltd., a biopharmaceutical company based in Vancouver, has announced an increase in its non-brokered private placement. Initially set at $2.1 million, the placement now totals $2.16 million due to increased demand, with shares priced at $0.085 each.

The company plans to use the funds for working capital and advancing its S-100 drug candidate for sickle cell disease. A portion will support Applied Lipid Technologies, Inc. in progressing towards clinical trials.

The second tranche awaits regulatory approval from the Canadian Securities Exchange. Issued securities will be subject to a four-month hold under Canadian law. Notably, these securities are not registered under the U.S. Securities Act and cannot be sold in the United States without an exemption.